Pharmaceutical company Gilead Sciences has struck deals with six generic manufacturers to produce affordable versions of lenacapavir — a twice-yearly injectable drug that has shown near-complete effectiveness at preventing HIV infection — in 120 low- and middle-income countries. The announcement marks one of the most significant access agreements for an HIV prevention drug in years, though health advocates warn that some of the world’s hardest-hit populations have been left out.
At a glance
- Lenacapavir access: Gilead Sciences has signed licensing agreements with six manufacturers across India, Egypt, Pakistan, and the U.S. to produce and sell generic versions of the drug in 120 countries classified as high-incidence and resource-limited.
- HIV prevention trials: Clinical trials demonstrated that lenacapavir stopped HIV infection entirely among girls and women in South Africa and Uganda, and offered near-complete protection in a second trial spanning Argentina, Brazil, Mexico, Peru, South Africa, Thailand, and the U.S.
- Generic drug pricing: Researchers estimate lenacapavir could be produced profitably for as little as $40 per patient per year — compared to the $42,250 annual list price under the brand name Sunlenca in the U.S.
Why this drug matters
For decades, HIV prevention has depended heavily on daily oral medication. Adherence is a persistent challenge, particularly for populations facing stigma, poverty, or limited healthcare access.
Lenacapavir changes that equation. Two injections per year — one every six months — dramatically simplifies the prevention regimen. In the trials, the results were extraordinary. Among cisgender women in sub-Saharan Africa, zero participants who received lenacapavir acquired HIV. In the broader second trial, protection was nearly complete.
UNAIDS Executive Director Winnie Byanyima called it potentially “gamechanging — if all who would benefit can access it.” That conditional clause carries real weight.
Who’s included — and who isn’t
The six licensed manufacturers — India’s Dr. Reddy’s Laboratories, Emcure Pharmaceuticals, and Hetero Labs, alongside U.S.-based Viatris unit Mylan, Egypt’s Eva Pharma, and Pakistan’s Ferozsons Laboratories — will produce and distribute affordable versions across 120 countries, most of them lower-income nations.
Gilead has also committed to bridging supply gaps by providing its own product while generic manufacturing scales up, prioritizing 18 high-HIV-rate countries including Botswana, South Africa, and Thailand.
But the deal has drawn sharp criticism for what it excludes. Nearly all of Latin America falls outside the licensing agreement. According to UNAIDS, 41% of new HIV infections occur in upper-middle-income countries — exactly the income bracket most conspicuously absent from the deal.
Dr. Mohga Kamal-Yanni of the People’s Medicines Alliance criticized Gilead for negotiating directly with manufacturers rather than routing the agreements through the Medicines Patent Pool, the UN-backed mechanism designed to expand access to essential medicines. She said the agreements include conditions that would prevent the six licensed manufacturers from selling to excluded countries — even those that might pursue compulsory licensing under international trade law.
The access gap that remains
Compulsory licensing — a legal mechanism that allows countries to override drug patents in public health emergencies — exists as a fallback. But as Kamal-Yanni noted, it’s a route “fraught with difficulties” that can invite legal challenges from pharmaceutical companies. It’s a right, but not a simple one to exercise.
UNAIDS has also flagged that specific pricing details remain undisclosed. Advocates want full transparency on what countries will actually pay, and whether those prices will hold over time as newer manufacturers enter the market.
Gilead has said it plans to file for global regulatory approval of lenacapavir as a prevention regimen by the end of 2024 C.E. That timeline matters: approvals determine when generic manufacturers can formally enter markets and begin distribution at scale.
A breakthrough with conditions attached
Lenacapavir’s clinical results are genuinely remarkable — among the strongest ever recorded for an HIV prevention intervention. UNAIDS praised Gilead for licensing the medicine before waiting for full registration, calling that approach a model for how pharmaceutical companies should respond to global health crises.
Still, the exclusion of much of Latin America, and the absence of pricing transparency, mean this deal lands as a significant step rather than a complete solution. The World Health Organization estimates approximately 39 million people were living with HIV globally as of 2022 C.E., with 1.3 million new infections recorded that year. The countries left outside this agreement account for a substantial share of that ongoing toll.
The science has delivered something remarkable. The harder work — making sure that science reaches everyone it could protect — is still underway.
Read more
For more on this story, see: The Guardian
For more from Good News for Humankind, see:
- Alzheimer’s risk cut in half by drug in landmark prevention trial
- Renewables now make up at least 49% of global power capacity
- The Good News for Humankind archive on global health
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
More Good News
-
U.S. researchers cut Alzheimer’s risk by half in first-ever prevention trial
Alzheimer’s prevention may have reached a turning point after a landmark trial showed that removing amyloid plaques before symptoms appear can cut the risk of developing the disease by roughly 50%. Researchers at Washington University School of Medicine studied people with rare genetic mutations that make Alzheimer’s nearly inevitable, finding that early, aggressive treatment can genuinely alter the disease’s course. The results, published in The Lancet Neurology, mark the first time any intervention has shown potential to prevent Alzheimer’s from appearing at all, not merely slow its progression. That distinction matters enormously, since amyloid begins accumulating in the brain two…
-
Marie-Louise Eta becomes first female head coach in men’s top-five European leagues
Female head coach Marie-Louise Eta made history on April 11, 2026, when Union Berlin appointed her as interim head coach — becoming the first woman ever to hold a head coaching position in any of men’s top-five European leagues. The Bundesliga club made the move after dismissing Steffen Baumgart, with five matches remaining and real relegation stakes on the line. Eta, 34, had served as assistant coach since 2023 and was already a familiar, trusted presence within the squad. This was no ceremonial gesture — she was handed a survival fight, which is precisely what makes the milestone significant.
-
Renewables hit 49% of global power capacity for the first time
Renewable energy capacity crossed a landmark threshold in 2025, with global installed power surpassing 5,100 gigawatts and representing 49% of all capacity worldwide for the first time in history. The International Renewable Energy Agency reported a single-year addition of 692 gigawatts, led overwhelmingly by solar power, which alone accounted for 75% of new renewable installations. Clean energy now represents 85.6% of all new power capacity added globally, signaling that the transition has moved from aspiration to economic reality. The milestone carries implications beyond climate — nations with strong renewable bases demonstrated measurably greater energy security amid ongoing geopolitical instability.
